The Carbonic Anhydrase IX‐Activated Nanosensor for Dual‐Modal Imaging and Synergistic Phototherapy of Glioblastoma
Small Methods · 2026-06 · 10 (12)
DOI: 10.1002/smtd.70684 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small Methods, online erschienen am 01.05.2026. Verfasst von Qian Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Chemical Resource Engineering, College of Chemistry, Beijing University of Chemical Technology, Beijing, China. Hauptthemen laut MEDLINE: Glioblastoma, Carbonic Anhydrase IX, Brain Neoplasms, Phototherapy. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Natural Science Foundation of China, Beijing Natural Science Foundation, Interdisciplinary Research Center of Beijing University of Chemical Technology.
Abstract (Originalsprache)
Precise diagnosis and treatment of glioblastoma (GBM) remain challenging. The overexpression level of carbonic anhydrase IX (CA IX), a key biomarker for GBM, is correlated with tumor malignancy. Herein, we reported a CA IX‐activated nanosensor (MPC@BDPCA NPs) for near‐infrared imaging and synergistic phototherapy of orthotopic GBM. The tailor‐made core agent, a BODIPY derivative (BDPCA) incorporates a benzenesulfonamide moiety that selectively binds to CA IX, inducing rotational restriction of the probe and resulting in fluorescence turn‐on response. Owing to this specific activating mechanism, BDPCA enables a high‐contrast fluorescence and photoacoustic dual‐modal imaging for quantitative CA IX sensing. Notably, an extended π‐conjugation combined with a donor–acceptor molecular design optimizes both radiative and nonradiative decay pathways, affording efficient photothermal conversion and reactive oxygen species generation under 660 nm irradiation. To enhance blood‐brain barrier (BBB) penetration in orthotopic GBM models, BDPCA was encapsulated within pH‐degradable polymer shell via in situ polymerization, employing 2‐methacryloyloxyethyl phosphorylcholine (MPC) as monomer to improve biocompatibility and facilitate receptor‐mediated BBB transport. The resulting MPC@BDPCA NPs exhibit selective CA IX sensing, multimodal imaging capability, efficient BBB penetration, and potent synergistic phototherapy. This work highlights a versatile nanoscale sensing and diagnostic platform for precision imaging and therapeutic intervention of GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Chemical Resource Engineering, College of Chemistry, Beijing University of Chemical Technology, Beijing, China.
- Oncology Department, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Xiangchen Li, Yulong Jin, Yongji Tian, Zhuo Wang
Förderung
- Natural Science Foundation of China
- Beijing Natural Science Foundation
- Interdisciplinary Research Center of Beijing University of Chemical Technology
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Wu, Q., Zhang, G., Zhu, M., Si, L., Li, X., Liang, F., Jin, Y., Tian, Y., & Wang, Z. (2026). The Carbonic Anhydrase IX‐Activated Nanosensor for Dual‐Modal Imaging and Synergistic Phototherapy of Glioblastoma. Small Methods, 10(12). https://doi.org/10.1002/smtd.70684
Vancouver
Wu Q, Zhang G, Zhu M, Si L, Li X, Liang F, et al. The Carbonic Anhydrase IX‐Activated Nanosensor for Dual‐Modal Imaging and Synergistic Phototherapy of Glioblastoma. Small Methods. 2026;10(12). doi:10.1002/smtd.70684
BibTeX
@article{Wu2026,
author = {Wu, Qian and Zhang, Guoyang and Zhu, Mingguang and Si, Linxing and Li, Xiangchen and Liang, Fanghui and Jin, Yulong and Tian, Yongji and Wang, Zhuo},
title = {The Carbonic Anhydrase IX‐Activated Nanosensor for Dual‐Modal Imaging and Synergistic Phototherapy of Glioblastoma},
journal = {Small Methods},
year = {2026},
volume = {10},
number = {12},
doi = {10.1002/smtd.70684}
}
EUVIMED